Pharm

Serotonin Syndrome

search

Serotonin Syndrome

  • See Also
  1. Serotonin
  2. Neurotransmitter Physiology
  3. Neuroleptic Malignant Syndrome
  4. Malignant Hyperthermia
  • Background
  • History
  1. Libby Zion was a young patient who died of Serotonin Syndrome in 1984 and set historic precedent
    1. Provider education regarding Serotonin Syndrome
    2. Principal case that limited intern and resident shift hours
    3. http://en.wikipedia.org/wiki/Libby_Zion_law
  • Epidemiology
  1. Complicates 14-16% of SSRI Overdoses
    1. Isbister (2004) J Toxicol Clin Toxicol 42(3): 277-85 [PubMed]
  • Etiology
  1. Excessive Serotonin levels at the receptor sites
  2. Associated with combinations of Serotoninergic drugs
  3. Exacerbated by drugs that increase Serotonin levels
    1. Psychiatric medications
      1. Selective Serotonin Reuptake Inhibitors - SSRI (e.g. Paroxetine - Paxil)
      2. Serotonin-Norepinephrine Reuptake Inhibitors - SNRI (e.g. Venlafaxine - Effexor)
      3. MAO inhibitors (e.g. Phenelzine or Nardil)
      4. Tricyclic Antidepressants (e.g. Amitriptyline)
      5. Lithium
      6. Buspar
      7. Trazodone
      8. Some Antipsychotic Medications (e.g. Olanzapine or Zyprexa)
    2. Stimulant Medications
      1. Methylphenidate (Ritalin)
      2. Sibutramine (Meridia)
    3. Antiemetics
      1. Metoclopramide (Reglan)
      2. Ondansetron (Zofran)
      3. Droperidol (Inapsine)
    4. Migraine and Seizure Medications
      1. Triptans (e.g. SumatriptanImitrex)
      2. Ergot Alkaloids
      3. Valproic Acid (Depakote, Depakene)
      4. Carbamazepine (Tegretol)
    5. Synthetic Opioid Analgesics
      1. Tramadol (Ultram)
      2. Meperidine (Demerol)
      3. Fentanyl (Duragesic)
      4. Methadone
      5. Dextromethorphan
      6. Rare case reports with Buprenorphine (Suboxone), Hydromorphone, Oxycodone or Hydrocodone
    6. Muscle Relaxants
      1. Cyclobenzaprine (Flexeril)
      2. Metaxalone (Skelaxin)
    7. Miscellaneous medications
      1. Chlorpheniramine
      2. Linezolid (Zyvox) - MAO inhibitor effect
      3. Reserpine
      4. Ritonavir (Norvir)
    8. Herbals and supplements
      1. St. John's Wort
      2. Ginkgo Biloba
      3. Ginseng
      4. L-Tryptophan
      5. 5-Hydroxytryptophan (dietary supplement) - Serotonin precursor
      6. Yohimbine
    9. Recreational drugs
      1. Cocaine
      2. 3,4-methylenedioxmethamphetamine (Ecstacy)
      3. Methamphetamine
  • Risk Factors
  1. Medications with serotonergic effects (see above)
    1. Combined use of multiple serotonergic drugs
    2. Inadequate washout period between transitioning to a new serotonergic drug
    3. Higher Incidence with Monoamine Oxidase Inhibitors, St. John's Wort and Linezolid
  2. Cytochrome P450 Drug Interactions or specific patient Phenotypes making them more susceptible to Serotonin Syndrome
  3. Medical conditions that decrease the available monoamine oxidase
    1. Hypertension
    2. Atherosclerosis
    3. Hyperlipidemia
  • Diagnosis
  1. Mental Status Changes
    1. Confusion or Disorientation (51%)
    2. Agitation or irritability (34%)
    3. Coma or unresponsiveness (29%)
  2. Autonomic changes
    1. Fever or hyperthermia (45%)
    2. Diaphoresis (45%)
    3. Sinus Tachycardia (36%)
    4. Hypertension (35%)
    5. Mydriasis (28%) or unreactive pupils (20%)
    6. Tachypnea (26%)
    7. Nausea (23%)
  3. Neuromuscular changes
    1. Myoclonic Jerks (58%)
    2. Hyperreflexia (52%)
    3. Muscle rigidity (51%)
    4. Restlessness or hyperactivity (48%)
    5. Tremor (43%)
    6. Ataxia or Incoordination (40%)
    7. Clonus (23%)
      1. Spontaneous Clonus with a history of Serotoninergic agent use is pathognomonic for Serotonin Syndrome
      2. Dunkley (2003) QJM 96 (9): 635-642 [PubMed]
  4. Exclude other possible causes
    1. Infectious, metabolic, Substance Abuse or withdrawal
    2. No recent Neuroleptic changes
  • Differential Diagnosis
  1. Meningitis or Encephalitis
  2. Anticholinergic Syndrome
  3. Malignant Hyperthermia
  4. Neuroleptic Malignant Syndrome
    1. Occurs with Dopamine blocking agents
    2. Classic triad of fever, muscle rigidity and Altered Mental Status
  • Management
  1. Discontinue Serotoninergic medication
  2. Provide supportive care
  3. Treat muscle rigidity, Tremor and hyperthermia
    1. First line
      1. Benzodiazepines
    2. Refractory (severe, critically ill patients)
      1. Intubation
      2. Sedation and Paralytic Agents
  4. Consider Serotonin antagonists
    1. Cyproheptadine (Periactin)
      1. Initial protocol
        1. Bolus: 12 mg oral bolus dose for 1 dose
        2. Continued symptoms: 2 mg every 2 hours until symptoms controlled
      2. Maintenance protocol (once stabilized)
        1. Dose: 8 mg every 6 hours or 4 mg every 2-4 hours
        2. Maximum: 0.5 mg/kg/day
  5. Other medications that have been used for Serotonin Syndrome symptom control
    1. Propranolol
  6. Precautions
    1. Avoid Antipsychotics (e.g. Haloperidol) as has serotonergic effects and may exacerbate condition
    2. Avoid antipyretics
      1. Hyperthermia of Serotonin Syndrome is due to increased muscle activity (not the Hypothalamus)
  • Course
  1. Many cases likely go undiagnosed and resolve spontaneously when patients stop the medications themselves
  2. Resolution after stopping Serotoninergic medication
    1. Within 24 hours in 70% of cases
    2. Within 96 hours in almost all cases
  3. High acuity care
    1. Intensive Care admission in up to 40% of cases
    2. Mechanical Ventilation in up to 25% of cases
  4. Rarely fatal: 11 deaths in literature
  • References
  1. Herbert and Jhun in Herbert (2015) EM:Rap 15(4):14
  2. Nordt and Swadron in Majoewsky (2012) EM:Rap 12(2): 3
  3. Ables (2010) Am Fam Physician 81(9): 1139-42 [PubMed]
  4. Bodner (1995) Neurology 45:219-23 [PubMed]
  5. Brown (1996) Ann Pharmacother 30:529-33 [PubMed]
  6. Corkeron (1995) Med J Aust 163:481-2 [PubMed]
  7. Erner (2003) Pain Med 4(1): 63-74 [PubMed]
  8. Iqbal (2012) Ann Clin Psychiatry 24(4): 310-8 [PubMed]
  9. Kovich (2015) Am Fam Physician 92(2): 94-100 [PubMed]
  10. Mills (1995) Am Fam Physician 52(5):1475-82 [PubMed]